EP1086250A2 - Verfahren zur herstellung von nukleinsäurehybriden zur mutationsanalyse - Google Patents
Verfahren zur herstellung von nukleinsäurehybriden zur mutationsanalyseInfo
- Publication number
- EP1086250A2 EP1086250A2 EP99939503A EP99939503A EP1086250A2 EP 1086250 A2 EP1086250 A2 EP 1086250A2 EP 99939503 A EP99939503 A EP 99939503A EP 99939503 A EP99939503 A EP 99939503A EP 1086250 A2 EP1086250 A2 EP 1086250A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequences
- primers
- sense strand
- linker
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000035772 mutation Effects 0.000 title claims abstract description 23
- 238000004458 analytical method Methods 0.000 title claims abstract description 6
- 102000039446 nucleic acids Human genes 0.000 title description 3
- 108020004707 nucleic acids Proteins 0.000 title description 3
- 150000007523 nucleic acids Chemical class 0.000 title description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 63
- 108020004414 DNA Proteins 0.000 claims abstract description 51
- 230000000295 complement effect Effects 0.000 claims abstract description 33
- 230000037452 priming Effects 0.000 claims abstract description 18
- 102000053602 DNA Human genes 0.000 claims abstract description 16
- 239000011541 reaction mixture Substances 0.000 claims abstract description 15
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 13
- 108091081021 Sense strand Proteins 0.000 claims abstract description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 238000000137 annealing Methods 0.000 claims description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 6
- 229960000643 adenine Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 claims 1
- 102100029075 Exonuclease 1 Human genes 0.000 claims 1
- 239000000047 product Substances 0.000 description 34
- 239000012634 fragment Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108700024394 Exon Proteins 0.000 description 16
- 238000003776 cleavage reaction Methods 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 102000007517 Neurofibromin 2 Human genes 0.000 description 14
- 108010085839 Neurofibromin 2 Proteins 0.000 description 14
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 14
- 208000022032 neurofibromatosis type 2 Diseases 0.000 description 14
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 108010006785 Taq Polymerase Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000001351 cycling effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101710110830 Beta-agarase Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091023043 Alu Element Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
Definitions
- the present invention relates to a method of producing a DNA hybrid molecule comprised of a contiguous linear array of three or more sequences of interest (or potential interest) in predetermined relationship to each other.
- a further application in which it may be desirable to provide a DNA hybrid molecule is DNA sequencing.
- the amplified gene fragments from the separate PCR reactions are then purified, combined together and subjected to cycles of denaturing, reannealing and strand synthesis. As a result of these cycles, the complementary linker sequences hybridise to each other and are extended to produce a double stranded molecules which comprise the two gene fragments connected by the linker sequences.
- the Gene splicing by overlap extension method requires fragments to b joined in a pairwise fashion thus including additional laborious steps of purification and re- amplification for the creation of constructs of more than two fragments. Furthermore, although the Gene Fusion method utilises Taq polymerase no account is taken in the primer design of the 3' dA overhangs introduced by Taq. Consequently with the primer design employed in US-A-5 023 171, the majority of fragments will have 3' mismatches leading to inefficient fusion of the two fragments.
- a further technique for producing DNA hybride molecules is Gene Fusion as disclosed in Nucleic Acids Research, 17, 4895, (1989) (Yon & Freide) where a single linking primer is used to fuse the fragments. This is unlikely to be at all efficient for the fusion of more than two fragments since the PCR products themselves act as substitutes for primers for the whole of the fusion reaction leading to inefficient intermediate formation. Also with this published technique with only two fragments there is contamination by unfused products within the reaction.
- WO- A-9215678 (Stratagene) which describes a PCR-based process for generating a library of dicistronic DNA molecules (comprising upstream and downstream cistrons) for producing antibodies.
- the disclosure contemplates combining, in a single reaction vessel, (i) a repertoire of first polypeptide genes with a PCR primer pair therefor, one of the primers having a first 5 '-terminal non-priming portion providing a linking sequence; and
- the first and second 5'-terminal portions are such that they are capable of hybridising to form a duplex encoding a double-stranded cistronic bridge for linking the upstream and downstream cistrons.
- the library of dicistronic molecules is generated.
- each of the first and second stage PCR reactions employs Taq as a thermostable polymerising enzyme.
- those primers having linker sequences are designed such that their linker sequence is connected to their respective priming sequence via an adenosine residue. This takes account of the 3' adenine overhang added by Taq at the 3' end of an extended strand.
- Primers incorporating the extra adenosine residue may of course be used both in conjunction with any other polymerising enzyme which adds a 3'-adenosine overhang at the end of an extended strand and those which do not.
- thermostable polymerase which may or may not add a 3' adenine overhang to the end of an extended strand.
- the invention enables a DNA hybrid molecule comprised of the sequences x,, x 2 x n (and their respective complements x,', x 2 ' x ⁇ ') in predetermined linked relationship to be produced in high yield from the respective individual sequences provided at diverse regions of the same or different DNA molecules.
- the linker sequences which are used are independent of the sequences which are to be assembled into the intended hybrid molecule. Furthermore the incorporation of the additional adenosine residue for primers to be used in conjunction with Taq as the polymerising enzyme avoids 3' mismatches leading to inefficient fusion of fragments.
- sequences x, x 2 x n may for example be exons which are separated by any distance (possibly of unknown sequence) along a particular DNA molecule whereas in the hybrid molecule produced by the method of the invention the sequences are spaced from each other by a relatively short, and known, sequence of, say, 20 to 30 bases.
- Hybrid molecules produced in accordance with the method of the invention may for example be constructed for the purposes of mutation detection. More particularly, the hybrid molecule may comprise a plurality of exons (in which one or more mutations may be present) in a molecule having a length of up to 1.5 kb thus permitting mutation scanning of all of these exons using a technique such as CCM, EMC, NIRCA or PTT. A further possibility is a hybrid molecule comprised of a plurality of exons which may be constructed to enable more efficient sequencing of exons (as compared to their sequencing the exons at their locations in the endogenous DNA molecule).
- a further possibility is that the method of the invention is used for the construction of hybrid genes.
- the method of the invention involves two PCR reaction steps which allow the desired DNA hybrid molecule to be produced from the individual sequences xicide x 2 x n (and their complements x,', x 2 x n ) which are provided in a single reaction mixture. It will however be appreciated that, in certain circumstances, only one or other of the sets of complementary the sequences (x, x 2 x n ) or (x,' x 2 ' x-,') may initially be present at the start of the first PCR reaction, in which case the "missing" complementary sequences are generated in situ in the initial PCR reaction stage.
- PCR primers for each set of complementary sequences (xicide x,'), (x 2 , x 2 ') (x n , x n ') which are to be present in the intended DNA hybrid molecule.
- the primers hybridising to the 3' ends of the sequences x,' and x n may be "standard" PCR primers and may hybridise either to the sequences x,' or x n (as the case may be) or to a region external thereto (since the 3' ends of the sequences x and x n to be incorporated in the hybrid molecule are determined by the primers used in the second stage of the PCR reaction (see below)).
- the other primers for the first stage of PCR reaction are in effect modified PCR primers and comprise a priming sequence (i.e. a sequence which will hybridise to the appropriate x or x' sequence in the manner of a standard PCR primer) attached to a linker sequence.
- a priming sequence i.e. a sequence which will hybridise to the appropriate x or x' sequence in the manner of a standard PCR primer
- linker primers are also referred to herein as "linker primers”
- the linker sequences are such that the primers which hybridise to the 3' ends of any two sequences (x i5 x (i+1) )where i is 1 to (n-1) have linker sequences which are specifically complementary to each other, i.e. these linker sequences will hybridise to each other but not to any other sequences in the reaction mixture.
- the manner in which the linker sequences function to provide for assembly of the required DNA hybrid molecule will be more fully appreciated from the description given below
- the linker sequences may for example be comprised of 20 to 30 bases and are ideally such that they do not have any secondary structure (e.g. "hairpins"). It is preferred that the annealing temperature (Tm) of the complementary pairs are substantially the same and is 2-5°C higher than the annealing temperature of the primers to the x and x' sequences.
- Tm annealing temperature
- linker primers for the assembly (using PCR reactions employing Taq as the polymerising enzyme) of a hybrid DNA molecule comprised of five sequences x,_ 5 and their respective complements.
- specific sequence is the priming portion of the linker primer.
- the "a” represented in bold is an additional adenosine residue incorporated in the primer to take account of the 3' adenosine overhang added by Taq at the end of an extended strand.
- the linker primers and preferably also the standard PCR primers for the 3' ends of the sequences x,' and x n , are provided in a limiting concentration.
- a "limiting concentration” is a concentration of primers in a PCR reaction leading to inefficient amplification and such that an increase in concentration results in an increase in product yield.
- the ratio of primers to single copy template in the limiting PCR reaction may typically be about 1 x 10 6 :1 to about 1 x 10 8 :1 (e.g. about 3 x 10 7 :1).
- a standard limiting concentration may for example be 40nM. The limiting concentration may however readily be determined empirically for each set of primers used.
- the first stage PCR reaction may be conducted under the conditions (e.g. polymerase enzyme, nucleotides, buffers, temperature cycling etc.) will be understood by those skilled in the art.
- the temperature cycling may involve stages of denaturation at 90°C, hybridisation at 60°C, and strand synthesis at 72°C.
- the polymerase enzyme which is used for the first stage reaction is one formulated so as to be activated by heat (e.g. at 90° to 95°C) so that there are no non-specific hybridisations being extended at low temperature.
- Heat activated polymerase enzymes are know to those skilled in the art and examples of such enzymes which may be employed in the method of the invention include AmpliTaq Gold (ex Perkin Elmer) and Platinum Taq (ex Gibco BRL).
- the product of the first stage PCR reaction is treated, prior to the second stage, to prevent the extension of unwanted non-stringent hybridisations between residual primers and the template DNA.
- This ensures a proper "Hot Start" for the second stage PCR reaction.
- This treatment may for example comprise an exonuclease digestion involving addition of exonuclease to the first stage reaction mixture followed by incubation of the mixture at 37°C (e.g. for 15 min) and then at 80°C (e.g. for 30 min) so as to remove any single stranded molecules.
- the first stage reaction mixture is cooled, e.g. at -20°C, to inactivate residual DNA polymerase activity.
- the second stage reaction there is employed an excess of two PCR primers one of which hybridises to the 3' end of sequence x,' and the other of which hybridises to the 3' end of the sequence x n (and which therefore respectively provide the 5' ends of the sense and anti-sense strands of the intended hybrid molecule).
- the excess is a concentration of primers such that an increase in concentration does not produce an increase in yield.
- the "excess" may readily be determined by a person skilled in the art and for a typical reaction might for example be 500nM.
- Fresh polymerising enzyme is used for the second stage PCR reaction and this is preferably a heat activated polymerase enzyme as described for the first stage reaction.
- the second stage reaction may be conducted under temperature cycling conditions as described for the first stage reaction.
- Fig. 1 illustrates a DNA hybrid molecule and a "naturally occurring" DNA molecule from which it is produced
- Fig. 2 illustrates steps in the conversion of the "naturally occurring" DNA molecule to the hybrid molecule.
- Figs. 3 to 7 illustrate the results of the Examples.
- the invention is described by way of example only with reference to the synthesis of a DNA hybrid molecule 1 (see Fig. 1) comprised of exons present in a naturally occurring DNA molecule 2 (see Fig. 1). More particularly, the molecule 2 is shown as being comprised of sense and anti-sense strands 3 and 4 respectively with the former incorporating exons x trench x 2 , x 3 x terrain of interest (e.g. for the purpose of mutation analysis). These sequences x,, x 2 , x 3 x n have their respective complementary sequences x,', x 2 ', x 3 ' x n ' in the anti-sense strand 4 shown and may for example be separated from each other by several hundred bases.
- the hybrid molecule 1 is illustrated as having sense and anti-sense strands 5 and 6 respectively with the former incorporating the sequences x réelle x 2 , x 3 x n and the latter incorporating sequences x,', x 2 ', x 3 ' x_'.
- sequences x, and x 2 are connected (reading in the 5' to 3' direction) by the sequence -t-L 12 -a " where a and t represent adenine and thymidine residues respectively and L 12 is a linker sequence (the subscript "12" indicating that the linker is between sequences x, and x 2 .
- sequences x 2 and x 3 are connected by the sequence -t-L 23 -a and so forth.
- Fig. 2 illustrates the manner in which molecule 1 is synthesised from molecule 2. More particularly, the synthesis involves a two stage PCR reaction employing heat activated Taq as the polymerising enzyme and in which the first stage utilises limiting concentrations of a plurality of pairs of modified PCR primers, one pair for each of sequences (xicide x,'), (x 2 , x 2 '), (x 3 , x 3 ')
- the primer pair comprises
- a first primer having a priming sequence which will specifically hybridise to the 3' region of the "sense sequence" x. and which is connected at its 5'-end to a linker sequence L'. _ 0+1) via an adenine residue ("a");
- a second primer having a priming sequence which will specifically hybridise to the 3' region of the "antisense sequence" x,' connected at its 5'-end to a linker sequence L , via an adenine residue ("a").
- the primer pair for sequence (x,, x,') comprises a primer as defined under (i) above (in which the linking sequence is L 12 ) and a conventional PCR primer (PI) specific for the 3' region of sequence x,'.
- the primer pair for sequences x n , x n ' comprises a primer as defined under (ii) above (in which the linking sequence is L (n . 1) n ) and a conventional PCR (P2) primer specific for the 3' region of sequence x,..
- linker sequences which form part of the modified PCR primers are such that they do not have any internal secondary structure (e.g. "hairpins") and that two such complementary sequences have an annealing temperature (T m ) which slightly exceeds that of the priming sequence and its complement. Examples of suitable linker sequences have been given above.
- the "starting" DNA molecule 2 is treated with the sets of primers as described together with a heat activated Taq polymerase (e.g. having an activation temperature of ca 94°C) in an appropriate buffer.
- a heat activated Taq polymerase e.g. having an activation temperature of ca 94°C
- all of the primers are present in limiting concentration.
- the first stage is conducted under conditions of temperature cycling such that there is an initial, relatively high temperature, denaturation step (e.g. at 95°C), followed by a hybridisation step (e.g. at 60°C) followed by a strand synthesis step (e.g. at 72°C).
- an initial, relatively high temperature, denaturation step e.g. at 95°C
- a hybridisation step e.g. at 60°C
- a strand synthesis step e.g. at 72°C.
- a PCR reaction is effected resulting in the generation of the "short" products (see Fig. 2) in which the 3'- ends of all x and x' sequences (except x, and x n ') are connected to their respective linker sequences via an adenine residue "a" and the 5'-ends of all sequences (except x,' and x n ) are connected to their respective linker sequences via a thymidine residue "t". Furthermore, it will be noted that the 3 '-end of each of the short products has an adenine residue as added by the Taq polymerase.
- a terminal linking sequence of such longer product so generated may be able to hybridise with a terminal linking sequence of a further "longer" product or of a short product so that further extension is possible to produce fragments of greater length.
- the generation of the longer products may take place partly in the first stage reaction and partly in the second stage reaction (discussed below) although we do not wish to preclude the possibility that these products are formed wholly in either the first or second stage reaction. It is for this reason that the generation of the "longer” products is illustrated within the box defined by dashed lines and the first and second stages of the PCR reactions are connected by dashed arrows.
- the reaction mixture is preferably frozen to -20°C to deactivate any residual polymerase activity.
- flanking primers which define the 5' ends of the sense and anti-sense strands of the intended hybrid molecule are added to the reaction mixture.
- Fig. 2 illustrates these flanking primers are illustrated as FP1 and FP 2 together with the locations at which they hybridise.
- further polymerase which is activated only at elevated temperature together with buffers, nucleotides etc.
- the reaction mixture is then subjected to temperature cycling as previously i.e. denaturation (e.g. at 95°C for 1 min), hybridisation e.g. at 60°C (e.g. for 1 min) and synthesis (e.g. at 72°C for 2 minutes).
- the polymerase Since the polymerase is only activated at elevated temperature, it is ensured that any sequences which randomly hybridise during the initial heating of the reaction mixture become denatured before the temperature at which the polymerase is activated so that there are substantially no extension reactions resulting from these hybridisations. Put another way, the only hybridisations which occur above the activation temperature of the polymerase are those which are required for generation of the hybrid molecule 1 as explained more fully below.
- primers p, and p 2 may be external to the sequences x 1 , and x n respectively.
- a supplementary adenine residue was inserted between the genomic and 5' complementary segments of the self assembling primers in order to accommodate the 3' adenine overhangs added by Taq polymerase to the nascent DNA strand. All primers were checked for homology to Alu repeat sequences using the BLAST analysis program available at http://www.ncbi.nlm.nih.gov/cgi- bin/BLAST/nph-blast. Table 1 gives the sequences and T m s of the 12 primers used in the NF2 exon 6-10 array.
- DNA was extracted from peripheral blood lymphocytes on an Applied Biosystems 380A DNA extractor.
- PCR amplification of the self assembling DNA arrays was carried out in two stages. The primary reactions were carried out in 20 ⁇ l volumes using 50ng of genomic DNA, 40nmol.L ⁇ l of primers 1-10 (Table 1), 750 ⁇ mol.L"l of each dNTP, 0.6U Platinum Taq polymerase (GibcoBRL) in a lxPCR buffer comprising 67mM Tris-HCl (pH8.3 @ 25°C), 16.6mM ammonium sulphate, 3.7mM MgCl2 and
- PCR amplification was carried out on Perkin-Elmer 2400 or 9600 thermal cyclers using the following parameters; initial denaturation 94°C (3 mins), 30 cycles of 94°C (1 min); 60°C (1 min); 72°C (2 mins) followed by a final synthesis of 72°C (10 mins). Immediately on completion of cycling the primary PCR reactions were frozen at -20°C to inactivate residual DNA polymerase activity.
- Table 1 Primer sequences for amplification of NF2 exon 6-10 self-assembling array. Primers 2 through to 9 are all internal to the self assembling array and contain one of four pairs of complementary 5' termini which are highlighted in italics.
- the extra adenine nucleotide incorporated to accommodate the 3' terminal adenine residue added by Taq polymerase to the nascent strand is underlined in bold type.
- the melting temperature (T m ) of the respective genomic or linker portions of each of the primers is also indicated.
- the secondary reactions were carried out in separate 20 ⁇ l volumes using 2 ⁇ L of the primary PCR, 500nmol.L ⁇ l of primers 11 and 12 (Table 1), 200 ⁇ mol.L ⁇ l of each dNTP, 0.6U Platinum Taq polymerase (GibcoBRL) in a lxPCR buffer comprising 50mM Tris-HCl (pH9.0 @ 25°C), 20mM ammonium sulphate and 1.5mM MgCl2- The thermal cycling conditions were identical to those used for the primary amplifications.
- the internal primers (11 & 12) were either unlabelled (sequencing and CCM probe DNA) or 5' biotin labelled (CCM test DNA).
- CCM test DNA 5' biotin labelled (CCM test DNA).
- secondary PCRs were set up with primary PCRs from normal control DNA, with the addition of TAMRA labelled dCTP (Perkin-Elmer) to a final concentration of 800nmol.L " of secondary PCRs. Otherwise reaction conditions were identical to those described previously for secondary PCRs.
- each sample was sequenced in both orientations using either primers 11 or 12 with BigDye terminator cycle sequencing kits (Perkin-Elmer, Applied Biosystems)). The manufacturer's protocols were followed with the exception that the annealing temperature for the cycle sequencing reaction was increased from 50°C to 55°C to reflect the high T m of primers 11 and 12. The sequencing reactions were then electrophoresed and collected on an Applied Biosystems 377 fluorescent sequencer using 48cm well to read plates.
- Heteroduplexes were formed by heating equal quantities of unpurified biotinylated test DNA with unpurified internally TAMRA labelled normal control probe DNA at 94°C for 5 mins followed by annealing at 65°C for 12 hours.
- the heteroduplexed DNA was purified by electrophoresing each sample through a 1% low gelling temperature agarose gel and cutting out the 1046bp band using a sterile scalpel.
- the volume of gel slice was estimated by weighing and the gel slice equilibrated for 20 mins in an equal volume of 1 x ⁇ -Agarase buffer comprising lOmM Bis-Tris HC1 (pH6.5) and ImM EDTA.
- the ⁇ -Agarase buffer was then removed and the gel slice heated at 70°C for 10 mins to liquefy the agarose followed by cooling to 37°C.
- a further equal volume of 1 x ⁇ -Agarase buffer was added followed by 1U of ⁇ -Agarase I (USB Biochemical). The gel slice was then digested overnight at 37°C.
- heteroduplexes were then left to complex with the beads for 1 hour at 42°C.
- the samples were then placed on a magnet to separate the beads and the supernatant carefully removed using a pipette.
- the beads with bound DNA were resuspended in 20 ⁇ L of a solution of ImM
- the beads Prior to piperidine cleavage the beads were rinsed once with 50 ⁇ L of TE buffer. Then the beads were resuspended in 5 ⁇ L of a 1M solution of piperidine in deionised formamide to which Genescan 2500 Rox size standard (Perkin-Elmer) and dextran blue loading dye (Sigma) had been added. The samples were heated at 90°C for 30 mins to cleave the modified bases, snap chilled on ice and placed on a magnet to separate the beads from the unbound DNA now in the liquid phase.
- Genescan 2500 Rox size standard Perkin-Elmer
- dextran blue loading dye Sigma
- Figs 4a and 4b show the product of step 1.1.2 sequenced from both termini.
- Fig 5a shows sequencing in the forward orientation using primer 11.
- Fig 4b shows sequencing in the reverse orientation using primer 12.
- the positions of the intron exon boundaries, primer annealing sites and linker sequences are indicated on the electropherograms. The product was seen to comprise the expected exons in the correct orientations. No discernible degradation of sequence was observed across the transitions from one component to the next.
- step 1.1.2 The procedure of step 1.1.2 was repeated for a range of genomic DNA samples and consistently yielded fragments of the expected size. Reaction yields were generally high ( ⁇ 500ng per lO ⁇ l) with low background (see Fig 5a).
- products from a series of 7 heterozygotes for NF2 mutations spread throughout four of the five NF2 CR exons were directly sequenced to confirm that the genotype present in genomic DNA was correctly represented in the product.
- the 7 mutant heterozygotes were as follows nt600-3OG (exon 7), nt676-7T>G (exon 8), nt713delC (exon 8), nt7840T (exon 8), nt855delT (exon 9), nt887delT (exon 10) and nt948G>T + nt949G>T (exon 10).
- Fig 6 gives example data from four representative mutation heterozygotes.
- 11 NF2 mutant heterozygotes were then retrospectively screened using a modified fluorescent solid-phase CCM method based on that of Rowley et al, as disclosed in Genomics 30, 574-582. The products were internally labelled using TAMRA dCTP in preference to end labelling. This method helps eliminate false positives resulting from background cleavage.
- Cleavage of internally labelled products should result in two labelled fragments with a total molecular weight equal to the uncleaved product.
- Mismatched cytosines were modified using hydroxylamine.
- mismatched thymines were modified using the potassium permanaganate in preference to osmium tetroxide.
- nt676-2A>T The mutation not detected by either condition, nt676-2A>T, is predicted to produce heteroduplexes detectable only by potassium permanganate modification (T:T/A:A mismatches). Furthermore, two other mutations producing heteroduplexes with mismatched thymines (nt784C>T and nt903C>T) had undetectable levels of cleavage after potassium permanganate modification. However, both these mutations also produce mismatched cytosines which were detected after hydroxylamine modification. All of the mutations predicted to produce heteroduplexes with mismatched cytosines produced visible cleavage products after hydroxylamine modification.
- a supplementary unmatched adenine residue was inserted between the genomic and 5' linker segments of the self assembling primers in order to accommodate the 3' adenine overhangs added by Taq polymerase to the nascent DNA strand. All primers were checked for homology to Alu repeat sequences using the BLAST analysis program available at http://www.ncbi.nlm.nih.gov/cgi- bin/BLAST/nph-blast.
- step 1.1.2 The procedure of step 1.1.2 was repeated for a range of genomic DNA samples and consistently yielded fragments of the expected size. Reaction yields were generally high ( ⁇ 500ng per lO ⁇ l) with low background (see Fig 5b).
- Genomic sequences of NF2 exons 6-10 amplified by the self assembling array Exonic sequence is indicated by capitals, intronic sequence is in lower case.
- the annealing sites of primers used in the primary PCR reaction to generate the five self assembling DNA fragments are marked in bold underlined sequence.
- the annealing sites of the internal primer pair used during the secondary PCR to drive the array assembly are marked in underlined italics.
- the primary and secondary primers for exon 10 reverse overlap, the region of overlap is marked in bold, underlined italics.
- AAGCCCAGGC CAGGGAGGAG AAGGCTAGAA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9812674.1A GB9812674D0 (en) | 1998-06-12 | 1998-06-12 | Nucleic acids |
GB9812674 | 1998-06-12 | ||
PCT/GB1999/001691 WO1999064624A2 (en) | 1998-06-12 | 1999-06-14 | Method of generating nucleic acid hybrids for mutation analysis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1086250A2 true EP1086250A2 (de) | 2001-03-28 |
Family
ID=10833627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99939503A Withdrawn EP1086250A2 (de) | 1998-06-12 | 1999-06-14 | Verfahren zur herstellung von nukleinsäurehybriden zur mutationsanalyse |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1086250A2 (de) |
JP (1) | JP2002517258A (de) |
AU (1) | AU5377599A (de) |
CA (1) | CA2330252A1 (de) |
GB (1) | GB9812674D0 (de) |
WO (1) | WO1999064624A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2351853A1 (de) * | 2000-06-06 | 2011-08-03 | Life Technologies Corporation | Methode und Vorrichtungen für multiplex Amplifizierungsreaktionen |
US6605451B1 (en) * | 2000-06-06 | 2003-08-12 | Xtrana, Inc. | Methods and devices for multiplexing amplification reactions |
US7087414B2 (en) | 2000-06-06 | 2006-08-08 | Applera Corporation | Methods and devices for multiplexing amplification reactions |
US8323897B2 (en) | 2002-12-04 | 2012-12-04 | Applied Biosystems, Llc | Multiplex amplification of polynucleotides |
HU229967B1 (hu) | 2011-12-20 | 2015-03-30 | Kps Diagnosztika Zrt | Eljárás töredezett nukleinsavak szekvenciájának meghatározására |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613945A2 (de) * | 1993-02-25 | 1994-09-07 | The General Hospital Corporation | Tumorsuppressor-Gen Merlin und dessen Verwendungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023171A (en) * | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
WO1992015678A1 (en) * | 1991-03-01 | 1992-09-17 | Stratagene | Pcr generated dicistronic dna molecules for producing antibodies |
ATE361377T1 (de) * | 1997-09-29 | 2007-05-15 | Hope City | Leistungstarke verknüpfung von nukleinsäuresegmenten |
-
1998
- 1998-06-12 GB GBGB9812674.1A patent/GB9812674D0/en not_active Ceased
-
1999
- 1999-06-14 JP JP2000553614A patent/JP2002517258A/ja active Pending
- 1999-06-14 WO PCT/GB1999/001691 patent/WO1999064624A2/en not_active Application Discontinuation
- 1999-06-14 AU AU53775/99A patent/AU5377599A/en not_active Abandoned
- 1999-06-14 EP EP99939503A patent/EP1086250A2/de not_active Withdrawn
- 1999-06-14 CA CA002330252A patent/CA2330252A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613945A2 (de) * | 1993-02-25 | 1994-09-07 | The General Hospital Corporation | Tumorsuppressor-Gen Merlin und dessen Verwendungen |
Also Published As
Publication number | Publication date |
---|---|
CA2330252A1 (en) | 1999-12-16 |
GB9812674D0 (en) | 1998-08-12 |
WO1999064624A2 (en) | 1999-12-16 |
AU5377599A (en) | 1999-12-30 |
JP2002517258A (ja) | 2002-06-18 |
WO1999064624A3 (en) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pogulis et al. | In vitro recombination and mutagenesis by overlap extension PCR | |
US5759822A (en) | Method for suppressing DNA fragment amplification during PCR | |
US5834252A (en) | End-complementary polymerase reaction | |
JP6374964B2 (ja) | 特別なキャプチャープローブ(heatseq)を使用したシークエンスキャプチャー法 | |
US5525493A (en) | Cloning method and kit | |
US20030207279A1 (en) | Amplification of DNA to produce single-stranded product of defined sequence and length | |
EP1212449B1 (de) | Verfahren zur amplifikation von signal-flankierenden sequenzen aus unbekannten, genomischen daten | |
WO2007123742A2 (en) | Methods and compositions for increasing the fidelity of multiplex nucleic acid assembly | |
US20040091923A1 (en) | Linked linear amplification of nucleic acids | |
EP0854935B1 (de) | verfahren zur überlappenden genomsequenzierung | |
CA2001110A1 (en) | Compositions and process for amplifying and detecting nucleic acid sequences | |
WO1991018114A1 (en) | Polynucleotide amplification | |
EP2785865A1 (de) | Verfahren und kit zur rna-charakterisierung in einer zusammensetzung | |
WO2003033718A1 (en) | Synthesis of oligonucleotides on solid support and assembly into doublestranded polynucleotides | |
Buzdin et al. | GREM, a technique for genome-wide isolation and quantitative analysis of promoter active repeats | |
JP2002535999A (ja) | ゲノム分析方法 | |
Moss | History and development of molecular biology | |
US6335184B1 (en) | Linked linear amplification of nucleic acids | |
WO1999064624A2 (en) | Method of generating nucleic acid hybrids for mutation analysis | |
EP3237635B1 (de) | Verfahren zur herstellung von sequenzierbereiten fragmenten mit hilfe von "bubble primer" | |
CN113913493A (zh) | 一种靶基因区域快速富集方法 | |
JP4455335B2 (ja) | 核酸増幅方法及び一塩基多型検出方法 | |
EP3759243B1 (de) | Verfahren und zusammensetzungen zur anreicherung von nukleinsäuren | |
Warshawsky et al. | Mapping protein-DNA interactions using in vivo footprinting | |
JP4681129B2 (ja) | 核酸末端領域の非対称的修飾法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010110 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE DK ES FI FR GB IE IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 20020125 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040907 |